PR97912

LONDON, Sept. 20, 2022 /PRNewswire=KYODO JBN/ --

    -- Features proprietary OXINIUM(TM) DH material; eliminates Cobalt Chrome

alloy reducing wear and corrosion risks [1]

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today

announces the launch of its OR3O Dual Mobility System for use in primary and

revision hip arthroplasty in Japan. Compared with traditional solutions, dual

mobility implants have a small diameter femoral head that locks into a larger

polyethylene insert - increasing stability, reducing dislocation risk, and

offering improved range of motion.[2]

Photo - https://mma.prnewswire.com/media/1901757/Smith_Nephew_OR3O.jpg

Logo - https://mma.prnewswire.com/media/3924/Smith_Nephew_Logo.jpg

While most competitive devices utilize a Cobalt Chrome (CoCr) liner along with

CoCr or ceramic head balls, OR3O incorporates Smith+Nephew’s latest advanced

bearing surface, OXINIUM DH, for its liner and proprietary OXINIUM on XLPE for

its femoral head and polyethylene inserts. This eliminates both the modular

CoCr liner and/or CoCr head ball from the construct - reducing wear and

corrosion risks that have been associated with the alloy. [1]

OXINIUM DH (Diffusion Hardened) is a unique variation of Smith+Nephew’s OXINIUM

Technology platform that increases the depth of hardening through an additive

manufacturing process.

The modular dual mobility segment was introduced to Japan in 2013 and has

continued to grow globally. Post-operative dislocation is the second most

common reason for revision of a total hip replacement globally [3-6] and

remains a serious concern for surgeons when performing total hip arthroplasty.

Studies have shown dual mobility is uniquely positioned to manage dislocation,

better than metal-on-metal or ceramic-on-ceramic large head series. [7]

“Smith+Nephew’s OR3O Dual Mobility System is a groundbreaking introduction for

Japan that offers technology not available in competitive systems,” said Shinya

Dobashi, Senior Vice President and Managing Director, North Asia, Smith+Nephew.

“Over a dozen peer reviewed publications have now cited or expressed concerns

over corrosion or elevated ions in CoCr modular dual mobility liners.[8-20] The

reduced corrosion [1] of our OXINIUM and OXINIUM DH bearing surface sets OR3O

apart from the competition.”  

Smith+Nephew’s OR3O(TM) Dual Mobility System is available in Japan for both

primary and revision applications and offers cross-compatibility with the

R3(TM) Acetabular System.

References

    1. Parikh A; Pawar V; Sprague J. Long-term Simulator Wear Performance of an

       Advanced Bearing Technology for THA. Poster Presented at ORS. 2013;

       Poster No:1028

    2. Darrith B, Courtney P.M., Della Valle C.J. Outcomes of dual

       mobility components in total hip arthroplasty. Bone Joint J

       2018;100-B:11–19.

    3. Australian Orthopaedic Association National Joint Replacement

       Registry (AOANJRR). Hip, Knee & Shoulder Arthroplasty: 2021: 2021 Annual

       Report, Adelaide; AOA, 2021:

       [Available at: https://aoanjrr.sahmri.com/annual-reports-2021 ]

    4. National Joint Registry for England, Wales and Northern Ireland, 18th

       Annual Report [Available at: https://reports.njrcentre.org.uk/downloads ]

    5. American Joint Replacement Registry (AJRR), The Seventh Annual Report of

       the AJRR on Hip and Knee Arthroplasty 2021, American Academy of

       Orthopaedic Surgeons

    6. Italian Arthroplasty Register, Addendum to the Annual Report 2019,

       English Version of Tables and Figures, October 2020

    7. Boyer, B., Philippot, R., Geringer, J. & Farizon, F. (2011). ‘Primary

       total hip arthroplasty with dual mobility socketto prevent dislocation:

       a 22-year follow-up of 240 hips’, International Orthopaedics (SICOT)

       (2012) 36:511–518

    8. Spece, H., MacDonald, D. W., Mont, M. A., Lee, G.-C., and Kurtz, S. M.,

       “Fretting Corrosion and Polyethylene Damage Mechanisms in Modular Dual

       Mobility Total Hip Arthroplasty,”Beyond the   Implant:   Retrieval

       Analysis Methods for Implant Surveillance, ASTM STP1606

    9. Nam,D., Salih,R., Nahhas,C., Barrack,R. And Nunley,R, (2019). ‘Is a

       modular dual mobility acetabulum a viable option for the young, active

       total hip arthroplasty patient?’, Bone Joint J 2019;101-B:365–371

   10. Matsen Ko,L., Pollag,K., Yoo,J., & Sharkey,P (2015). ‘Serum Metal Ion

       Levels Following Total Hip Arthroplasty With ModularDual Mobility

       Components’, The Journal of Arthroplasty 31 (2016) 186–189

   11. Civinini,R., Cozzi Lepri,A., Carulli,C., Matassi,F., Villano,M., &

       Innocenti,M. (2019). ‘Patients Following Revision Total Hip Arthroplasty

       With ModularDual Mobility Components and Cobalt-Chromium Inner MetalHead

       are at Risk of Increased Serum Metal Ion Levels’, The Journal of

       Arthroplasty 35 (2020) S294eS298

   12. Romero,J., Wach,A., Silberberg,S., Chiu,Y., Westrich,G., Wright,T., &

       Padgett,D. (2020) ‘2020 Otto Aufranc Award: Malseating of modular dual

       mobility liners; Incidence and Implications’ ,Bone Joint J 2020;102-B(7

       Supple B):20–26

   13. Lee,G., Kamath,A. & Maxwell Courtney,P. (2020). ‘Clinical Concerns With

       Dual Mobility- Should I Avoid it When Possible?’, Article in Press, The

       Journal of Arthroplasty xxx (2021) 1e4

   14. Gkiatas,I., Sharma,A., Greenberg,A., Duncan,S., Chalmers,B. & Sculco,P.

       (2020). ‘Serum metal ion levels in modular dual mobility acetabular

       components: A systematic review’, Journal of Orthopaedics 21 (2020) 432–

       437

   15. Steven M. Kurtz et al. (2015) ‘Is There Material Loss at the Backside

       Taper in Modular CoCr Acetabular Liners?’, Clinical Orthopaedics and

       Related Research, 473:275–285

   16. Lombardo,D., Siljander,M., Gehrke,C., Moore,D., Karadsheh,M. & Baker,E.

       (2018). ‘Fretting and Corrosion Damage of Retrieved Dual-Mobility

       TotalHip Arthroplasty Systems’, The Journal of Arthroplasty 34 (2019)

       1273e1278

   17. Kolz,J., Wyles,C., Van Citters,D., Chapman,R., Trousdale,R. & Berry,D.

       (2020). ‘In Vivo Corrosion of Modular Dual-Mobility Implants:A Retrieval

       Study’, The Journal of Arthroplasty 35 (2020) 3326e3329

   18. Sonn,K. & Meneghini,R. (2020). ‘Case report: Adverse Local Tissue

       Reaction due to Acetabular Corrosion in Modular Dual-Mobility

       Constructs’, Arthroplasty Today 6 (2020) 976e980

   19. Tarity,T., Koch,C., Burket,J., Wright,T. & Westrich,G. (2016). ‘Fretting

       and Corrosion at the Backside of Modular Cobalt ChromiumAcetabular

       Inserts: A Retrieval Analysis’, The Journal of Arthroplasty 32 (2017)

       1033e1039

   20. D. C. Markel, T. Bou-Akl, M. D. Rossi, N. Pizzimenti, B. Wu, W. Ren

       (2019). ‘Blood metal levels, leucocyte profiles, and cytokine profiles

       in patients with a modular dual-mobility hip prosthesis: Early results

       from a prospective cohort study’, Bone Joint J 2019;101-B:1035–1041

About Smith+Nephew

Smith+Nephew is a portfolio medical technology business focused on the repair,

regeneration and replacement of soft and hard tissue. We exist to restore

people’s bodies and their self-belief by using technology to take the limits

off living. We call this purpose ‘Life Unlimited’. Our 18,000 employees deliver

this mission every day, making a difference to patients’ lives through the

excellence of our product portfolio, and the invention and application of new

technologies across our three global franchises of Orthopaedics, Sports

Medicine & ENT and Advanced Wound Management.

Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and

generated annual sales of $5.2 billion in 2021. Smith+Nephew is a constituent

of the FTSE100 (LSE:SN, NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are

used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless

the context requires otherwise.

For more information about Smith+Nephew, please visit www.smith-nephew.com and

follow us on Twitter ( http://www.twitter.com/smithnephewplc ), LinkedIn (

http://www.linkedin.com/company/smith-%26-nephew ), Instagram  (

https://www.instagram.com/smithnephewmeded/ ) or Facebook (

http://www.facebook.com/smithnephewplc ).

Forward-looking Statements

This document may contain forward-looking statements that may or may not prove

accurate. For example, statements regarding expected revenue growth and trading

margins, market trends and our product pipeline are forward-looking statements.

Phrases such as "aim", "plan", "intend", "anticipate", "well-placed",

"believe", "estimate", "expect", "target", "consider" and similar expressions

are generally intended to identify forward-looking statements. Forward-looking

statements involve known and unknown risks, uncertainties and other important

factors that could cause actual results to differ materially from what is

expressed or implied by the statements. For Smith+Nephew, these factors

include: risks related to the impact of COVID-19, such as the depth and

longevity of its impact, government actions and other restrictive measures

taken in response, material delays and cancellations of elective procedures,

reduced procedure capacity at medical facilities, restricted access for sales

representatives to medical facilities, or our ability to execute business

continuity plans as a result of COVID-19; economic and financial conditions in

the markets we serve, especially those affecting health care providers, payers

and customers (including, without limitation, as a result of COVID-19); price

levels for established and innovative medical devices; developments in medical

technology; regulatory approvals, reimbursement decisions or other government

actions; product defects or recalls or other problems with quality management

systems or failure to comply with related regulations; litigation relating to

patent or other claims; legal compliance risks and related investigative,

remedial or enforcement actions; disruption to our supply chain or operations

or those of our suppliers (including, without limitation, as a result of

COVID-19); competition for qualified personnel; strategic actions, including

acquisitions and dispositions, our success in performing due diligence, valuing

and integrating acquired businesses; disruption that may result from

transactions or other changes we make in our business plans or organisation to

adapt to market developments; and numerous other matters that affect us or our

markets, including those of a political, economic, business, competitive or

reputational nature. Please refer to the documents that Smith+Nephew has filed

with the U.S. Securities and Exchange Commission under the U.S. Securities

Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual

report on Form 20-F, for a discussion of certain of these factors. Any

forward-looking statement is based on information available to Smith+Nephew as

of the date of the statement. All written or oral forward-looking statements

attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does

not undertake any obligation to update or revise any forward-looking statement

to reflect any change in circumstances or in Smith+Nephew's expectations.

(TM) Trademark of Smith+Nephew. Certain marks registered US Patent and

Trademark Office.

SOURCE  Smith & Nephew plc

Media Enquiries:  David Snyder, Smith+Nephew, +1 978-749-1440